Use of data-independent acquisition mass spectrometry for comparative proteomics analyses of sera from pregnant women with intrahepatic cholestasis of pregnancy

Shaohan Zou,Ruirui Dong,Jing Wang,Fengbing Liang,Tingting Zhu,Shaojie Zhao,Yan Zhang,Tiejun Wang,Ping Zou,Na Li,Yao Wang,Minjian Chen,Conghua Zhou,Ting Zhang,Liang Luo
DOI: https://doi.org/10.1016/j.jprot.2021.104124
IF: 3.855
2021-03-01
Journal of Proteomics
Abstract:<p>We used data-independent acquisition (DIA) proteomics technology followed by ELISAs and automated biochemical analyses to identify and validate protein expression levels in Intrahepatic Cholestasis of Pregnancy (ICP) and healthy pregnant controls. We employed bioinformatics to identify metabolic processes associated with differentially expressed proteins.The expression levels of two proteins (S100-A9 and the L-lactate dehydrogenase A chain) were significantly higher in ICP patients than in controls; the areas under the receiver operating characteristic (ROC) curves (AUCs) were 0.774 and 0.828, respectively. The expression levels of two other proteins (apolipoprotein A-I and cholinesterase) were significantly lower in patients, with values of 0.900 and 0.842, respectively. Multiple logistic regression showed that a combination of the levels of the four proteins optimized the AUC (0.962), thus more reliably diagnosing ICP. The levels of all four proteins were positively associated with that of total bile acids. Bioinformatics analyses indicated that the four proteins principally affected neutrophil activation involved in the immune response, cell adhesion, lipoprotein metabolism, and the PPAR signaling pathway.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Significance</h3><p>This preliminary work improves our understanding of changes in serum levels of protein in pregnant women with ICP. The four proteins may serve as novel noninvasive biomarkers for ICP.</p>
biochemical research methods
What problem does this paper attempt to address?
The problem this paper attempts to address is: by using data-independent acquisition (DIA) mass spectrometry technology, to compare the serum proteomes of patients with intrahepatic cholestasis of pregnancy (ICP) and healthy pregnant women, in order to identify and validate differentially expressed proteins, thereby discovering new ICP biomarkers and improving the diagnostic accuracy of ICP. Specifically, the researchers aim to solve this problem through the following steps: 1. **Using DIA technology**: Perform proteomic analysis on serum samples from ICP patients and healthy pregnant women to identify differentially expressed proteins. 2. **Validating differentially expressed proteins**: Further validate the expression levels of these proteins in ICP patients using ELISA and automated biochemical analysis methods. 3. **Evaluating the diagnostic value of biomarkers**: Assess the sensitivity and specificity of these proteins as ICP biomarkers through receiver operating characteristic (ROC) curve analysis. 4. **Exploring potential biological mechanisms**: Investigate the roles of these differentially expressed proteins in the pathogenesis of ICP through bioinformatics analysis. The main findings of the study include: - The expression levels of two proteins (S100-A9 and L-lactate dehydrogenase A chain) were significantly higher in ICP patients compared to the control group, with their ROC curve areas under the curve (AUC) being 0.774 and 0.828, respectively. - The expression levels of another two proteins (apolipoprotein A-I and cholinesterase) were significantly lower in ICP patients compared to the control group, with their AUCs being 0.900 and 0.842, respectively. - The combined detection of these four proteins can increase the AUC to 0.962, thereby diagnosing ICP more reliably. - These four proteins mainly affect neutrophil activation, immune response, cell adhesion, lipoprotein metabolism, and PPAR signaling pathways. These findings help improve the early diagnosis and treatment of ICP, providing new non-invasive biomarkers for clinical use.